Abstract
Angiotensin II (Ang-II) plays a role not only as a vasoconstrictor in controlling blood pressure and electrolyte and fluid homeostasis, but also as a mitogenic factor through the Ang-II type-1 (AT1) receptor in cardiovascular cells. Since a low prevalence of cancer in hypertensive patients receiving angiotensin converting enzyme inhibitors has been reported, the molecular mechanisms of the renin-angiotensin system (RAS) in cancer cells have been elucidated. Interestingly, there is increasing evidence that the RAS is implicated in the development of prostate cancer. As previously reported, AT1 receptor blockers (ARBs), a class of antihypertensive agent, have the potential to inhibit the growth of prostate cancer cells and tumors through the AT1 receptor. This review highlights that the RAS plays a potential role in various aspects of prostate cancer, and ARBs could be useful for treatment of prostate cancer or its chemoprevention.
Keywords: Angiotensin II, angiotensin II receptor blocker, castration resistant prostate cancer, local RAS, prostate cancer, renin-angiotensin system, Dihydrotestosterone, Estradiol, Guanosine phosphate binding protein coupled receptor, Interleukin, Monocyte chemoattractant protein-1, Signal transducer and activator of transcription 3, Tumor necrosis factor, Vascular endothelial factor, Peroxisome proliferator-activated receptor
Current Cancer Drug Targets
Title: Engagement of Renin-Angiotensin System in Prostate Cancer
Volume: 11 Issue: 4
Author(s): H. Uemura, K. Hoshino and Y. Kubota
Affiliation:
Keywords: Angiotensin II, angiotensin II receptor blocker, castration resistant prostate cancer, local RAS, prostate cancer, renin-angiotensin system, Dihydrotestosterone, Estradiol, Guanosine phosphate binding protein coupled receptor, Interleukin, Monocyte chemoattractant protein-1, Signal transducer and activator of transcription 3, Tumor necrosis factor, Vascular endothelial factor, Peroxisome proliferator-activated receptor
Abstract: Angiotensin II (Ang-II) plays a role not only as a vasoconstrictor in controlling blood pressure and electrolyte and fluid homeostasis, but also as a mitogenic factor through the Ang-II type-1 (AT1) receptor in cardiovascular cells. Since a low prevalence of cancer in hypertensive patients receiving angiotensin converting enzyme inhibitors has been reported, the molecular mechanisms of the renin-angiotensin system (RAS) in cancer cells have been elucidated. Interestingly, there is increasing evidence that the RAS is implicated in the development of prostate cancer. As previously reported, AT1 receptor blockers (ARBs), a class of antihypertensive agent, have the potential to inhibit the growth of prostate cancer cells and tumors through the AT1 receptor. This review highlights that the RAS plays a potential role in various aspects of prostate cancer, and ARBs could be useful for treatment of prostate cancer or its chemoprevention.
Export Options
About this article
Cite this article as:
Uemura H., Hoshino K. and Kubota Y., Engagement of Renin-Angiotensin System in Prostate Cancer, Current Cancer Drug Targets 2011; 11 (4) . https://dx.doi.org/10.2174/156800911795538101
DOI https://dx.doi.org/10.2174/156800911795538101 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Meet Our Editorial Board Member:
Anti-Cancer Agents in Medicinal Chemistry High-Dose Linoleic Acid Activated JAK2-STAT3 Signaling Pathway Involved in Cytokine Production and Lipogenesis in Pancreatic Exocrine Cells
Current Molecular Medicine The Molecular Mechanisms of TRAIL Resistance in Cancer Cells: Help in Designing New Drugs
Current Pharmaceutical Design Peptides Targeting Estrogen Receptor Alpha-Potential Applications for Breast Cancer Treatment
Current Pharmaceutical Design Colostral Proline-Rich Polypeptides - Immunoregulatory Properties and Prospects of Therapeutic Use in Alzheimers Disease
Current Alzheimer Research Phytometabolites Targeting the Warburg Effect in Cancer Cells: A Mechanistic Review
Current Drug Targets Leptin as a Cardiac Pro-Hypertrophic Factor and its Potential Role in the Development of Heart Failure
Current Pharmaceutical Design A Potent Anti-Carcinoma and Anti-Acute Myeloblastic Leukemia Agent, AG490
Anti-Cancer Agents in Medicinal Chemistry Emerging Role of Stromal Fibroblasts in Epithelial Cancer
Current Signal Transduction Therapy A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related Cancers
Current Medicinal Chemistry Editorial: Signalling Pathways in Virus-caused Cancers
Current Cancer Drug Targets Novel Agents in Anticancer Drug Therapy I (Antiangiogenic Agents, Egfr Inhibitors)
Medicinal Chemistry Reviews - Online (Discontinued) Treatment of Atopic Dermatitis: Current Status and Future Prospects
Current Drug Therapy The Effects of Kisspeptin in Human Reproductive Function – Therapeutic Implications
Current Drug Targets The Role of the Calcium-Sensing Receptor in Human Pathophysiology
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Novel Insights Into the Role of MicroRNA in Lung Cancer Resistance to Treatment and Targeted Therapy
Current Cancer Drug Targets Melatonin Leads to Axonal Regeneration, Reduction in Oxidative Stress, and Improved Functional Recovery Following Sciatic Nerve Injury
Current Neurovascular Research Patents on Enhancing the Potency and Longevity of Highly Valuable Protein Hormones
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery DNA Methyltransferases Inhibitors from Natural Sources
Current Topics in Medicinal Chemistry